Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D02TVQ
|
|||
Former ID |
DIB019955
|
|||
Drug Name |
GSK343
|
|||
Synonyms |
compound 6 [PMID 24900432]; GSK 343
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
Structure |
Download2D MOL
|
|||
Formula |
C31H39N7O2
|
|||
Canonical SMILES |
CCCC1=C(C(=O)NC(=C1)C)CNC(=O)C2=C3C=NN(C3=CC(=C2)C4=CC(=NC=C4)N5CCN(CC5)C)C(C)C
|
|||
InChI |
1S/C31H39N7O2/c1-6-7-23-14-21(4)35-31(40)26(23)18-33-30(39)25-15-24(16-28-27(25)19-34-38(28)20(2)3)22-8-9-32-29(17-22)37-12-10-36(5)11-13-37/h8-9,14-17,19-20H,6-7,10-13,18H2,1-5H3,(H,33,39)(H,35,40)
|
|||
InChIKey |
ULNXAWLQFZMIHX-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 1346704-33-3
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Enhancer of zeste homolog 1 (EZH1) | Target Info | Inhibitor | [1] |
Enhancer of zeste homolog 2 (EZH2) | Target Info | Inhibitor | [1] | |
KEGG Pathway | MicroRNAs in cancer | |||
NetPath Pathway | IL2 Signaling Pathway | |||
Reactome | PRC2 methylates histones and DNA | |||
Oxidative Stress Induced Senescence | ||||
PKMTs methylate histone lysines | ||||
WikiPathways | Interactome of polycomb repressive complex 2 (PRC2) | |||
Endoderm Differentiation | ||||
Integrated Pancreatic Cancer Pathway | ||||
Histone Modifications | ||||
Cell Differentiation - meta | ||||
miRs in Muscle Cell Differentiation | ||||
miR-targeted genes in muscle cell - TarBase | ||||
miR-targeted genes in lymphocytes - TarBase | ||||
miR-targeted genes in epithelium - TarBase |
References | Top | |||
---|---|---|---|---|
REF 1 | Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2. ACS Med Chem Lett. 2012 Oct 19;3(12):1091-6. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.